Therapeutic Innovation & Regulatory Science (TIRS), previously known as The Drug Information Journal, was launched as the official journal of DIA. The scope of Therapeutic Innovation & Regulatory Science reaches beyond the focus of pharmaceuticals, and its research and development, to include innovations in drugs, devices, and diagnostics, as well as global regulatory issues. Cutting edge articles on new science issues dedicated to fostering health and wellness worldwide will be included in each issue and feature hot topics such as CER, HTA, companion diagnostics, personalized medicine and more. Finally, Commentaries on emerging healthcare issues will continue to engage readers in the ongoing conversation between industry, academia, regulators and patients.

Editor
Gregory Daniel, PhD, MPH, RPh  Duke-Robert J. Margolis, MD Center for Health Policy, Washington, DC, USA
Editor-in-Chief
Gregory Daniel, PhD, MPH, RPh  Duke-Robert J. Margolis, MD Center for Health Policy, Washington, DC, USA
Editor Emeritus
J. Rick Turner, PhD, DSc       DRT Strategies, Inc, USA
Associate Editors
Richard Day, MD, FRACP     St. Vincent's Hospital, Sydney, NSW, Australia
Lisa Kammerman, PhD Kammerman Consulting, Chevy Chase, MD, USA
Grazyna (Gracie) Lieberman Genentech, San Francisco, CA, USA
Anne Rowzee, PhD      FDA/CDER, Silver Spring, MD, USA
Richard C. Zink, PhD     Target PharmaSolutions, Chapel Hill, NC, USA
Senior Managing Editor
Ranjini Prithviraj, PhD   DIA
Editorial Board
Theresa Allio, PhD, RAC       Advanced Accellerator Applications, New York City Area, NY, USA
Christopher P. Austin, MD   National Institutes of Health, Bethesda, MD, USA
Josephine Babiarz, JD   Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
Paul A. Bleicher, MD, PhD    Optum, Cambridge, MA, USA
Leona Blustein, PharmD      Actelion, a Janssen Pharmaceuticals Company of Johnson & Johnson, Philadelphia, PA, USA
David R. Bristol, PhD    Statistical Consulting Services LLC, Winston Salem, NC, USA
Joseph C. Cappelleri, PhD, MPH, MS  Pfizer Inc., New York, NY, USA
Andrzej Czarnecki, MD, PhD, DSc      Eli Lilly & Company, Windlesham, United Kingdom
Lode Dewulf, MD, Dip Pharm Med, FFPM  Corvalus, Neerijse, Belgium
Joseph A. DiMasi, PhD  Tufts University, Boston, MA, USA
Rafe Donahue, PhD      BioMimetic Therapeutics, Inc, Franklin, TN, USA
Sara Doshi, PharmD     Eli Lilly and Company, Libertyville, IL, USA
Todd A. Durham, MS    Novan, Inc., Durham, NC, USA
Ronald D. Fitzmartin, PhD, MBA  FDA/CDER, Silver Spring, MD, USA
Erick J. Gaussens, PhD  ProductLife Group, Suresnes, France
Barbara Gladson, PT, OT, PhD     Rutgers Biomedical & Health Sciences, Short Hills, NJ, USA
Alan M. Hochberg, BS  F. Hoffmann-La Roche Ltd, Basel, Switzerland
Stuart Horowitz, PhD, MBA  WIRB-Copernicus Group, Princeton, NJ, USA
Mitchell W. Krucoff, MD, FACC, FAHA, FSCAI   Duke University, Durham, NC, USA
Craig H. Lipset, MPH    Pfizer Inc., New York, NY, USA
Wendy Lipworth, MBBS, PhD      The University of Sydney, Sydney, NSW, Australia
Christopher-Paul Milne, DVM, MPH, JD    Tufts University, Boston, MA, USA
Shunsuke Ono, PhD     The University of Tokyo,Tokyo, Japan
Min Soo Park, MD, PhD       Yonsei University College of Medicine, Seoul, Republic of Korea
Monika Pietrek, MD, PhD, MSc   Pietrek Associates GmbH, Weinheim, Germany
Peter J. Pitts   Adherent Health, LLC; Center for Medicine in the Public Interest, New York, NY, USA
Ronald J. Portman, MD Novartis Pharmaceutical Corporation, East Hartford, CT, USA
Daniel Reshef Bristol Myers Squibb Company, Princeton, NJ, USA
Ramses F. Sadek, PhD  Augusta University, Augusta, GA, USA
Jonathan Seltzer, MD, MBA, MA, FACC     Applied Clinical Intelligence, Bala Cynwyd, PA, USA
E. Mitchell Seymour, PhD, RAC   University of Michigan, Ann Arbor, MI, USA
R. William Soller, PhD   Soller Regulatory and Research Services, Houston, TX, USA
Amy Sun, MD, PhD, FACP    Sanofi-Aventis, Bridgewater, NJ, USA
Tetsuya Tanimoto, MD Jyoban Hospital of Tokiwa Foundation, Fukushima, Japan